CYC · ASX

Cyclopharm Limited (ASX:CYC)

AU$1.07

 0.005 (0.469%)
ASX:Live
17/04/2025 04:10:20 PM
HALO Ords HALO Growth HALO Earnings Momentum HALO Consensus Value GROWTH AUS +3
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CYC Overview

CYC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Weak

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Weak

Balance Sheet

Very Strong

About CYC

Website

Cyclopharm Limited

Telephone

61.2.9541.0411

Address

Unit 4 1 The Crescent Kingsgrove, New South Wales (NSW) 2208

Description

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. It operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.

CYC Price Chart

Key Stats

Market Cap

AU$118.36M

PE

0.00

EV/EBITDA

0.0

Dividends Overview

DIV Yield

.7%

Franking

N/A

Ex Dividend Date (est.)

01-Sep-23

Market Data

52 weeks range

Low 1.02 - 2.5

Trade Value (12mth)

AU$40,361.00

1 week

-3.17%

1 month

-24.91%

YTD

-32.49%

1 year

-39.89%

All time high

3.45

Key Fundamentals

EPS 3 yr Growth

127.70%

EBITDA Margin

-47.30%

Operating Cashflow

-$13m

Free Cash Flow Return

-29.00%

ROIC

-30.50%

Interest Coverage

-40.90

Quick Ratio

2.70

Other Data

Shares on Issue (Fully Dilluted)

111m

HALO Sector

Healthcare

Next Company Report Date

25-Feb-26

Ex Dividend Date (est.)

01-Sep-23

Next Dividend Pay Date (est.)

11-Sep-23

Reporting Currency

AUD

Short Sell (% of issue)

0.08

CYC Announcements

Latest Announcements

Date Announcements

10 April 25

Technegas Installed at First DoD Hospital

×

Technegas Installed at First DoD Hospital

09 April 25

Revised Date of Annual General Meeting

×

Revised Date of Annual General Meeting

01 April 25

Technegas US Momentum Accelerates with $US1m Sales Milestone

×

Technegas US Momentum Accelerates with $US1m Sales Milestone

27 March 25

Annual Report to shareholders

×

Annual Report to shareholders

27 March 25

Appendix 4G & Corporate Governance Statement

×

Appendix 4G & Corporate Governance Statement

19 March 25

Company Update

×

Company Update

19 March 25

CYC to present at NWR Virtual Healthcare Conference

×

CYC to present at NWR Virtual Healthcare Conference

17 March 25

Webinar - Cyclopharm Business Update

×

Webinar - Cyclopharm Business Update

14 March 25

CYC signs 5-year Agreement with USA Veterans Administration

×

CYC signs 5-year Agreement with USA Veterans Administration

10 March 25

Date of Annual General Meeting

×

Date of Annual General Meeting

26 February 25

Change of Director's Interest Notice - JW

×

Change of Director's Interest Notice - JW

26 February 25

Change of Director's Interest Notice - DH

×

Change of Director's Interest Notice - DH

25 February 25

Preliminary Final Report

×

Preliminary Final Report

25 February 25

CYC Results Summary

×

CYC Results Summary

28 January 25

Change in substantial shareholding from AEF

×

Change in substantial shareholding from AEF

23 January 25

CYC Signs US National Agreement with HCA for Technegas

×

CYC Signs US National Agreement with HCA for Technegas

06 January 25

Response to ASX Price Query

×

Response to ASX Price Query

20 December 24

Cyclopharm's USA Technegas Expansion Update

×

Cyclopharm's USA Technegas Expansion Update

09 December 24

US Clinical Paper - Technegas for Lung Transplant Evaluation

×

US Clinical Paper - Technegas for Lung Transplant Evaluation

03 December 24

First Patients Imaged with Technegas - French Clinical Trial

×

First Patients Imaged with Technegas - French Clinical Trial

27 November 24

CYC Receives First Technegas Orders from US VA Hospitals

×

CYC Receives First Technegas Orders from US VA Hospitals

19 November 24

Cyclopharm Bell Potter Healthcare Conference Presentation

×

Cyclopharm Bell Potter Healthcare Conference Presentation

03 October 24

CYC Signs Agreement with VA and First DoD Order Received

×

CYC Signs Agreement with VA and First DoD Order Received

01 October 24

Change of Director's Interest Notice - JW

×

Change of Director's Interest Notice - JW

03 September 24

Cyclopharm - 2024 First Half Results & USA Expansion Update

×

Cyclopharm - 2024 First Half Results & USA Expansion Update

CYC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 -0.05 -0.13 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 -0.05 -0.13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -27.4 29.3 -152.9 Lock Lock Lock
     PE X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 -0.06 -0.09 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.10 -0.09 -0.13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.7 -15.3 -40.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -8.2 -4.7 -8.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 -50.0 -100.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.8 0.6 0.7 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.39 0.34 0.38 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.33 0.28 0.33 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.1 -15.7 17.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 92 93 103 Lock Lock Lock
Basic m Lock Lock Lock Lock 92 93 103 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 23 26 28 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.1 13.4 4.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 13 14 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 6 4 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 85.5 -37.8 -81.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock 25.6 14.0 2.4 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 74 86 98 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -9 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.9 -43.1 -43.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -27.3 -34.5 -47.3 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -7 -10 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.1 -37.7 -44.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -31.4 -38.1 -52.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 -5 -14 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 1 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -7 -5 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.2 28.9 -180.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -28.5 -17.8 -47.9 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -7 -7 -13 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 2 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -2 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -1 -1 22 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -7 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -221.1 6.3 -79.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.3 -0.3 -0.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 20 12 21 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 50 46 62 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 4 4 8 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -16 -7 -12 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 13 14 19 Lock Lock Lock
Equity $m Lock Lock Lock Lock 37 32 43 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 41 36 50 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.2 -10.8 38.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -13.3 -10.2 -21.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -18.1 -14.6 -30.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -16.5 -25.9 -33.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -15.0 -12.2 -30.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -15.1 -18.7 -29.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -23.9 -42.1 -40.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.5 0.8 0.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -43.7 -23.2 -28.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.6 3.5 4.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.6 2.3 2.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 55.0 38.8 48.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -84.0 -83.0 -118.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.9 3.4 3.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.5 2.5 2.3 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.8 1.2 0.9 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 18.9 11.9 13.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.5 0.6 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.5 0.6 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -33.0 -18.9 -50.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -15.5 -10.9 -22.5 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -13.3 -10.2 -21.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.4 1.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -18.1 -14.6 -30.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 113.9 109.9 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -20.6 -16.0 -30.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 145.8 148.4 158.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 124.3 108.1 102.9 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 270.1 256.6 261.5 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 59.8 60.8 42.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 210.3 195.7 219.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

01-Sep-23

DIV Yield

.7%

Franking Level

N/A

DPSg

-100.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.08%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CYC Shortsell

Frequently Asked Questions

The current share price of Cyclopharm Limited (CYC:ASX) is AU$1.07.
The 52-week high share price for Cyclopharm Limited (CYC:ASX) is AU$2.50.
The 52-week low share price for Cyclopharm Limited (CYC:ASX)? is AU$1.02.
The current TTM dividend payout for Cyclopharm Limited (CYC:ASX) is 0.70.
The last dividend payment of Cyclopharm Limited (CYC:ASX) is AU$0.01.
Cyclopharm Limited (CYC:ASX) has a franking level of 0.0%.
Cyclopharm Limited (CYC:ASX) is classified in the Healthcare.
The current P/E ratio for Cyclopharm Limited (CYC:ASX) is 0.00.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.